| MicrobiologyBytes: Maths & Computers for Biologists: ANOVA with SPSS | Updated: April 26, 2007 | Search |
Never, ever, run any statistical test without performing EDA first!
What's wrong with t-tests?
Nothing, except ...
If you want to compare three or more groups using t-tests with the usual 0.05
level of significance, you would have to compare the three groups pairwise (A
to B,
A
to C, B to C),
so
the
chance
of getting the wrong result would
be:
1 - (0.95 x 0.95 x 0.95) = 14.3%
If you wanted to compare four or more groups, the chance of getting the wrong result would be (0.95)6 = 26%, and for five groups, 40%. Not good, is it? So we use ANOVA. Never perform multiple t-tests: Anyone on this module discovered performing multiple t-tests when they should use ANOVA will be shot!
ANalysis Of VAriance (ANOVA) is such an important statistical method that it would be easy to spend a whole module on this test alone. Like the t-test, ANOVA is a parametric test which assumes:
so it's important to carry out EDA before starting AVOVA! In fact, ANOVA is quite a robust procedure, so as long as the groups are similar, the test is normally reliable.
ANOVA tests the null hypothesis that the means of all the groups being compared are equal, and produces a statistic called F which is equivalent to the t-statistic from a t-test. But there's a catch. If the means of all the groups tested by ANOVA are equal, fine. But if the result tells us to reject the null hypothesis, we still don't know which of the means differ. We solve this problem by performing what is known as a "post hoc" (after the event) test.
Reminder:
ANOVA jargon:
The array of options for different ANOVA tests in SPSS is confusing, so I'll go through the most important bits using some examples.
Data:
Pain Scores for Analgesics |
|
Drug: |
Pain Score: |
| Diclofenac | 0, 35, 31, 29, 20, 7, 43, 16 |
| Ibuprophen | 30, 40, 27, 25, 39, 15, 30, 45 |
| Paracetamol | 16, 33, 25, 32, 21, 54, 57, 19 |
| Asprin | 55, 58, 56, 57, 56, 53, 59, 55 |
Since it would be unethical to withhold pain relief, there is
no control group and we are just interested in knowing whether one drug
performs better (lower pain score) than another, so we need to perform a one-way/single-factor
ANOVA.
We enter this data into SPSS
using dummy values (1, 2, 3, 4) for the drugs so this numeric data can be used
in the ANOVA:

It's always a good idea to enter descriptive labels for data into the Variable View window, or the output is difficult to interpret!
EDA (Analyzer: Descriptive Statistics: Explore) shows that the data is normally distributed, so we can proceed with the ANOVA:
Analyze: Compare Means: One-Way ANOVA
Dependent variable: Pain Score
Factor: Drug:

Output:
| Levene Statistic | df1 | df2 | Sig. |
|---|---|---|---|
| 4.837 | 3 | 28 | .008 |
The significance value for homogeneity of variances is <.05, so the variances of the groups are significantly different. Since this is an assumption of ANOVA, we need to be very careful in interpreting the outcome of this test:
| Sum of Squares | df | Mean Square | F | Sig. | |
|---|---|---|---|---|---|
| Between Groups | 4956.375 | 3 | 1652.125 | 11.967 | .000 |
| Within Groups | 3865.500 | 28 | 138.054 | ||
| Total | 8821.875 | 31 |
This is the main ANOVA result. The significance value comparing the groups (drugs) is <.05, so we could reject the null hypothesis (there is no difference in the mean pain scores with the four drugs). However, since the variances are significantly different, this might be the wrong answer. Fortunately, the Welch and Brown-Forsythe statistics can still be used in these circumstances:
| Statistic | df1 | df2 | Sig. | |
|---|---|---|---|---|
| Welch | 32.064 | 3 | 12.171 | .000 |
| Brown-Forsythe | 11.967 | 3 | 18.889 | .000 |
The significance value of these are both <.05, so we still reject the null hypothesis. However, this result does not tell us which drugs are responsible for the difference, so we need the post hoc test results:
| (I) Drug | (J) Drug | Mean Difference (I-J) | Std. Error | Sig. | 95% Confidence Interval | ||
|---|---|---|---|---|---|---|---|
| Lower Bound | Upper Bound | ||||||
| Tukey HSD | 1 | 2 | -8.750 | 5.875 | .457 | -24.79 | 7.29 |
| 3 | -9.500 | 5.875 | .386 | -25.54 | 6.54 | ||
| 4 | -33.500(*) | 5.875 | .000 | -49.54 | -17.46 | ||
| 2 | 1 | 8.750 | 5.875 | .457 | -7.29 | 24.79 | |
| 3 | -.750 | 5.875 | .999 | -16.79 | 15.29 | ||
| 4 | -24.750(*) | 5.875 | .001 | -40.79 | -8.71 | ||
| 3 | 1 | 9.500 | 5.875 | .386 | -6.54 | 25.54 | |
| 2 | .750 | 5.875 | .999 | -15.29 | 16.79 | ||
| 4 | -24.000(*) | 5.875 | .002 | -40.04 | -7.96 | ||
| 4 | 1 | 33.500(*) | 5.875 | .000 | 17.46 | 49.54 | |
| 2 | 24.750(*) | 5.875 | .001 | 8.71 | 40.79 | ||
| 3 | 24.000(*) | 5.875 | .002 | 7.96 | 40.04 | ||
| Games-Howell | 1 | 2 | -8.750 | 6.176 | .513 | -27.05 | 9.55 |
| 3 | -9.500 | 7.548 | .602 | -31.45 | 12.45 | ||
| 4 | -33.500(*) | 5.194 | .001 | -50.55 | -16.45 | ||
| 2 | 1 | 8.750 | 6.176 | .513 | -9.55 | 27.05 | |
| 3 | -.750 | 6.485 | .999 | -20.09 | 18.59 | ||
| 4 | -24.750(*) | 3.471 | .001 | -36.03 | -13.47 | ||
| 3 | 1 | 9.500 | 7.548 | .602 | -12.45 | 31.45 | |
| 2 | .750 | 6.485 | .999 | -18.59 | 20.09 | ||
| 4 | -24.000(*) | 5.558 | .014 | -42.26 | -5.74 | ||
| 4 | 1 | 33.500(*) | 5.194 | .001 | 16.45 | 50.55 | |
| 2 | 24.750(*) | 3.471 | .001 | 13.47 | 36.03 | ||
| 3 | 24.000(*) | 5.558 | .014 | 5.74 | 42.26 | ||
| * The mean difference is significant at the .05 level. | |||||||
The Tukey test relies on homogeneity of variance, so we ignore
these results. The Games-Howell post-hoc test does not rely on homogeneity of
variance (this is why we used two different post-hoc tests) and so can be used.
SPSS kindly flags (*) which differences are significant!
Result: Drug 4 (Asprin) produces significantly different result
from the other
three drugs:
Formal Reporting: When we report the outcome of an ANOVA, we cite the value of the F ratio and give the number of degrees of freedom, outcome (in a neutral fashion) and significance value. So in this case:
There is a significant difference between the pain scores for asprin and the other three drugs tested, F(3,28) = 11.97, p < .05. |
Do anti-cancer drugs have different effects in males and females?
Data:
| Drug: | cisplatin |
vinblastine |
5-fluorouracil |
|||
Gender: |
Female |
Male |
Female |
Male |
Female |
Male |
| Tumour Size: |
65 |
50 |
70 |
45 |
55 |
35 |
70 |
55 |
65 |
60 |
65 |
40 |
|
60 |
80 |
60 |
85 |
70 |
35 |
|
60 |
65 |
70 |
65 |
55 |
55 |
|
60 |
70 |
65 |
70 |
55 |
35 |
|
55 |
75 |
60 |
70 |
60 |
40 |
|
60 |
75 |
60 |
80 |
50 |
45 |
|
50 |
65 |
50 |
60 |
50 |
40 |
|
We enter this data into SPSS using dummy values for the drugs (1, 2, 3) and genders (1,2) so the coded data can be used in the ANOVA:

It's always a good idea to enter descriptive labels for data into the Variable View window, or the output is difficult to interpret!
EDA (Analyze: Descriptive Statistics: Explore) shows that the data is normally distributed, so we can proceed with the ANOVA:
Analyze: General Linear Model: Univariate
Dependent variable: Tumour Diameter
Fixed Factors: Gender, Drug:

Also select:
Post Hoc: Tukey and Games-Howell:

Options:
Display Means for: Gender, Drug, Gender*Drug
Descriptive Statistics
Homogeneity tests:

Output:
| F | df1 | df2 | Sig. |
|---|---|---|---|
| 1.462 | 5 | 42 | .223 |
| Tests the null hypothesis that the error variance of the dependent variable is equal across groups. | |||
| a Design: Intercept+Gender+Drug+Gender * Drug | |||
The significance result for homogeneity of variance is >.05, which shows that the error variance of the dependent variable is equal across the groups, i.e. the assumption of the ANOVA test has been met.
| Source | Type III Sum of Squares | df | Mean Square | F | Sig. |
|---|---|---|---|---|---|
| Corrected Model | 3817.188(a) | 5 | 763.438 | 10.459 | .000 |
| Intercept | 167442.188 | 1 | 167442.188 | 2294.009 | .000 |
| Gender | 42.188 | 1 | 42.188 | .578 | .451 |
| Drug | 2412.500 | 2 | 1206.250 | 16.526 | .000 |
| Gender * Drug | 1362.500 | 2 | 681.250 | 9.333 | .000 |
| Error | 3065.625 | 42 | 72.991 | ||
| Total | 174325.000 | 48 | |||
| Corrected Total | 6882.813 | 47 | |||
| a R Squared = .555 (Adjusted R Squared = .502) | |||||
The highlighted values are significant (<.05), but there is no effect of gender (p = 0.451). Again, this does not tell us which drugs behave differently, so again we need to look at the post hoc tests:
| (I) Drug | (J) Drug | Mean Difference (I-J) | Std. Error | Sig. | 95% Confidence Interval | ||
|---|---|---|---|---|---|---|---|
| Lower Bound | Upper Bound | ||||||
| Tukey HSD | cisplatin | vinblastine | -1.25 | 3.021 | .910 | -8.59 | 6.09 |
| 5-flourouracil | 14.38(*) | 3.021 | .000 | 7.04 | 21.71 | ||
| vinblastine | cisplatin | 1.25 | 3.021 | .910 | -6.09 | 8.59 | |
| 5-flourouracil | 15.63(*) | 3.021 | .000 | 8.29 | 22.96 | ||
| 5-flourouracil | cisplatin | -14.38(*) | 3.021 | .000 | -21.71 | -7.04 | |
| vinblastine | -15.63(*) | 3.021 | .000 | -22.96 | -8.29 | ||
| Games-Howell | cisplatin | vinblastine | -1.25 | 3.329 | .925 | -9.46 | 6.96 |
| 5-flourouracil | 14.38(*) | 3.534 | .001 | 5.64 | 23.11 | ||
| vinblastine | cisplatin | 1.25 | 3.329 | .925 | -6.96 | 9.46 | |
| 5-flourouracil | 15.63(*) | 3.699 | .001 | 6.50 | 24.75 | ||
| 5-flourouracil | cisplatin | -14.38(*) | 3.534 | .001 | -23.11 | -5.64 | |
| vinblastine | -15.63(*) | 3.699 | .001 | -24.75 | -6.50 | ||
| Based on observed means. | |||||||
| * The mean difference is significant at the .05 level. | |||||||
In this example, we can use the Tukey or Games-Howell results. Again, SPSS helpfully flags which results have reached statistical significance. We already know from the main ANOVA table that the effect of gender is not significant, but the post hoc tests show which drugs produce significantly different outcomes.
Formal Reporting: When we report the outcome of an ANOVA, we cite the value of the F ratio and give the number of degrees of freedom, outcome (in a neutral fashion) and significance value. So in this case:
There is a significant difference between the tumour diameter for 5-flourouracil and the other two drugs tested, F(5,47) = 10.46, p < .05. |
Remember that one of the assumptions of ANOVA is independence of the groups being compared. In lots of circumstances, we want to test the same thing repeatedly, e.g:
This type of study reduces variability in the data and so increases the power to detect effects, but violates the assumption of independence, so as with the paired t-test, we need to use a special form of ANOVA called repeated measures. In a parametric test, the assumption that the relationship between pairs of groups is equal is called "sphericity". Violating sphericity means that the F statistic cannot be compared to the normal tables of F, and so software cannot calculate a significance value. SPSS includes a procedure called Mauchly's test which tells us if the assumption of sphericity has been violated:
If Mauchly’s test is significant then we cannot trust the F-ratios produced by SPSS unless we apply a correction (which, fortunately, SPSS helps us to do).
i.e. one independent variable, e.g. pain score after surgery:
Patient1 |
Patient2 |
Patient3 |
1 |
3 |
1 |
2 |
5 |
3 |
4 |
6 |
6 |
5 |
7 |
4 |
5 |
9 |
1 |
6 |
10 |
3 |
This data can be entered directly into SPSS. Note that each column represents a repeated measures variable (patients in this case). There is no need for a coding variable (as with between-group designs, above):

It's always a good idea to enter descriptive labels for data into the Variable View window, or the output is difficult to interpret! Next:
Analyze: General Linear Model: Repeated Measures

Within-Subject factor name: Patient
Number of Levels: 3 (because there are 3 patients)
Click Add, then
Define (factors):

There are no proper post hoc tests for repeated measures variables in SPSS. However, via the Options button, you can use the paired t-test procedure to compare all pairs of levels of the independent variable, and then apply a Bonferroni correction to the probability at which you accept any of these tests. The resulting probability value should be used as the criterion for statistical significance. A ‘Bonferroni correction’ is achieved by dividing the probability value (usually 0.05) by the number of tests conducted, e.g. if we compare all levels of the independent variable of these data, we make three comparisons and so the appropriate significance level is 0.05/3 = 0.0167. Therefore, we accept t-tests as being significant only if they have a p value <0.0167.

Output:
| Within Subjects Effect | Mauchly's W | Approx. Chi-Square | df | Sig. | Epsilon | ||
|---|---|---|---|---|---|---|---|
| Greenhouse-Geisser | Huynh-Feldt | Lower-bound | |||||
| patient | .094 | 9.437 | 2 | .009 | .525 | .544 | .500 |
Mauchly’s test is significant (p <.05) so we conclude that the assumption of sphericity has not been met.
| Source | Type III Sum of Squares | df | Mean Square | F | Sig. | |
|---|---|---|---|---|---|---|
| patient | Sphericity Assumed | 44.333 | 2 | 22.167 | 8.210 | .008 |
| Greenhouse-Geisser | 44.333 | 1.050 | 42.239 | 8.210 | .033 | |
| Huynh-Feldt | 44.333 | 1.088 | 40.752 | 8.210 | .031 | |
| Lower-bound | 44.333 | 1.000 | 44.333 | 8.210 | .035 | |
| Error(patient) | Sphericity Assumed | 27.000 | 10 | 2.700 | ||
| Greenhouse-Geisser | 27.000 | 5.248 | 5.145 | |||
| Huynh-Feldt | 27.000 | 5.439 | 4.964 | |||
| Lower-bound | 27.000 | 5.000 | 5.400 |
Because the significance values are <.05, we conclude that there was a significant difference between the three patients, but this test does not tell us which patients differed from each other. The next issue is which of the three corrections to use. Going back to Mauchly's test:
Post Hoc Tests:
| (I) patient | (J) patient | Mean Difference (I-J) | Std. Error | Sig.(a) | 95% Confidence Interval for Difference(a) | |
|---|---|---|---|---|---|---|
| Lower Bound | Upper Bound | |||||
| 1 | 2 | -2.833(*) | .401 | .003 | -4.252 | -1.415 |
| 3 | .833 | .946 | 1.000 | -2.509 | 4.176 | |
| 2 | 1 | 2.833(*) | .401 | .003 | 1.415 | 4.252 |
| 3 | 3.667 | 1.282 | .106 | -.865 | 8.199 | |
| 3 | 1 | -.833 | .946 | 1.000 | -4.176 | 2.509 |
| 2 | -3.667 | 1.282 | .106 | -8.199 | .865 | |
| Based on estimated marginal means | ||||||
| * The mean difference is significant at the .05 level. | ||||||
| a Adjustment for multiple comparisons: Bonferroni. | ||||||
Formal reporting:
Mauchly’s test indicated that the assumption of sphericity had been violated (chi-square = 9.44, p <.05), therefore degrees of freedom were corrected using Greenhouse-Geisser estimates of sphericity (epsilon = 0.53). The results show that the pain scores of the three patients differed significantly, F(1.05, 5.25) = 8.21, p <.05. Post hoc tests revealed that although the pain score of Patient2 was significantly higher than that of than Patient1 (p<.001), Patient3's score was not significantly differently from either of the other patients (both p>.05). |
i.e. two independent variables:
In a study of the best way to keep fields free of weeds for an entire growing season, a farmer treated test plots in 10 fields with either five different concentrations of weedkiller (independent variable 1) or five different length blasts with a flamethrower (independent variable 2). At the end of they growing season, the number of weeds per square metre were counted. To exclude bias (e.g. pre-existing seedbank in the soil), the following year, the farmer repeated the experiment but this time the treatments the fields received were reversed:
| Treatment: | Weedkiller
|
Flamethrower
|
||||||||
| Severity: | 1 |
2 |
3 |
4 |
5 |
1 |
2 |
3 |
4 |
5 |
| Field1 | 10 |
15 |
18 |
22 |
37 |
9 |
13 |
13 |
18 |
22 |
| Field2 | 10 |
18 |
10 |
42 |
60 |
7 |
14 |
20 |
21 |
32 |
| Field3 | 7 |
11 |
28 |
31 |
56 |
9 |
13 |
24 |
30 |
35 |
| Field4 | 9 |
19 |
36 |
45 |
60 |
7 |
14 |
9 |
20 |
25 |
| Field5 | 15 |
14 |
29 |
33 |
37 |
14 |
13 |
20 |
22 |
29 |
| Field6 | 14 |
13 |
26 |
26 |
49 |
5 |
12 |
17 |
16 |
33 |
| Field7 | 9 |
12 |
19 |
37 |
48 |
5 |
15 |
12 |
17 |
24 |
| Field8 | 9 |
18 |
22 |
31 |
39 |
13 |
13 |
14 |
17 |
17 |
| Field9 | 12 |
14 |
24 |
28 |
53 |
12 |
13 |
21 |
19 |
22 |
| Field10 | 7 |
11 |
21 |
23 |
45 |
12 |
14 |
20 |
21 |
29 |
SPSS Data View:

It's always a good idea to enter descriptive labels for data into the Variable View window, or the output is difficult to interpret:

Analyze: General Linear Model: Repeated Measures
Define Within Subject Factors (remember, "factor"
=
test or treatment):
Treatment, (2 treatments, weedkiller or flamethrower) (SPSS only allows 8 characters for the name)
Severity (5 different severities):

Click Define and define Within Subject Variables:

As above, there are no post hoc tests for repeated measures ANOVA in SPSS, but via the Options button, we can apply a Bonferroni correction to the probability at which you accept any of the tests:

Output:
| Within Subjects Effect | Mauchly's W | Approx. Chi-Square | df | Sig. | Epsilon | ||
|---|---|---|---|---|---|---|---|
| Greenhouse-Geisser | Huynh-Feldt | Lower-bound | |||||
| treatmen | 1.000 | .000 | 0 | . | 1.000 | 1.000 | 1.000 |
| severity | .092 | 17.685 | 9 | .043 | .552 | .740 | .250 |
| treatmen * severity | .425 | 6.350 | 9 | .712 | .747 | 1.000 | .250 |
The outcome of Mauchly’s test is significant (p <.05) for the severity of treatment, so we need to correct the F-values for this, but not for the treatments themselves.
| Source | Type III Sum of Squares | df | Mean Square | F | Sig. | |
|---|---|---|---|---|---|---|
| treatmen | Sphericity Assumed | 1730.560 | 1 | 1730.560 | 34.078 | .000 |
| Greenhouse-Geisser | 1730.560 | 1.000 | 1730.560 | 34.078 | .000 | |
| Huynh-Feldt | 1730.560 | 1.000 | 1730.560 | 34.078 | .000 | |
| Lower-bound | 1730.560 | 1.000 | 1730.560 | 34.078 | .000 | |
| Error(treatmen) | Sphericity Assumed | 457.040 | 9 | 50.782 | ||
| Greenhouse-Geisser | 457.040 | 9.000 | 50.782 | |||
| Huynh-Feldt | 457.040 | 9.000 | 50.782 | |||
| Lower-bound | 457.040 | 9.000 | 50.782 | |||
| severity | Sphericity Assumed | 9517.960 | 4 | 2379.490 | 83.488 | .000 |
| Greenhouse-Geisser | 9517.960 | 2.209 | 4309.021 | 83.488 | .000 | |
| Huynh-Feldt | 9517.960 | 2.958 | 3217.666 | 83.488 | .000 | |
| Lower-bound | 9517.960 | 1.000 | 9517.960 | 83.488 | .000 | |
| Error(severity) | Sphericity Assumed | 1026.040 | 36 | 28.501 | ||
| Greenhouse-Geisser | 1026.040 | 19.880 | 51.613 | |||
| Huynh-Feldt | 1026.040 | 26.622 | 38.541 | |||
| Lower-bound | 1026.040 | 9.000 | 114.004 | |||
| treatmen * severity | Sphericity Assumed | 1495.240 | 4 | 373.810 | 20.730 | .000 |
| Greenhouse-Geisser | 1495.240 | 2.989 | 500.205 | 20.730 | .000 | |
| Huynh-Feldt | 1495.240 | 4.000 | 373.810 | 20.730 | .000 | |
| Lower-bound | 1495.240 | 1.000 | 1495.240 | 20.730 | .001 | |
| Error(treatmen*severity) | Sphericity Assumed | 649.160 | 36 | 18.032 | ||
| Greenhouse-Geisser | 649.160 | 26.903 | 24.129 | |||
| Huynh-Feldt | 649.160 | 36.000 | 18.032 | |||
| Lower-bound | 649.160 | 9.000 | 72.129 |
Since there was no violation of sphericity, we can look at the comparison
of the two treatments without any correction. The significance value shows (0.000)
that there was a significant difference between the two treatments, but does
not tell us which treatments produced this effect.
The output also tells us the effect of the severity of treatments, but remember
there was a violation of sphericity here, so we must look at the corrected
F-ratios.
All of the corrected values are highly significant and so we can use the
Greenhouse-Geisser
corrected values as these are the most conservative.
| (I) severity | (J) severity | Mean Difference (I-J) | Std. Error | Sig.(a) | 95% Confidence Interval for Difference(a) | |
|---|---|---|---|---|---|---|
| Lower Bound | Upper Bound | |||||
| 1 | 2 | -4.200(*) | .895 | .011 | -7.502 | -.898 |
| 3 | -10.400(*) | 1.190 | .000 | -14.790 | -6.010 | |
| 4 | -16.200(*) | 1.764 | .000 | -22.709 | -9.691 | |
| 5 | -27.850(*) | 2.398 | .000 | -36.698 | -19.002 | |
| 2 | 1 | 4.200(*) | .895 | .011 | .898 | 7.502 |
| 3 | -6.200(*) | 1.521 | .028 | -11.810 | -.590 | |
| 4 | -12.000(*) | 1.280 | .000 | -16.723 | -7.277 | |
| 5 | -23.650(*) | 2.045 | .000 | -31.197 | -16.103 | |
| 3 | 1 | 10.400(*) | 1.190 | .000 | 6.010 | 14.790 |
| 2 | 6.200(*) | 1.521 | .028 | .590 | 11.810 | |
| 4 | -5.800 | 1.690 | .075 | -12.036 | .436 | |
| 5 | -17.450(*) | 2.006 | .000 | -24.852 | -10.048 | |
| 4 | 1 | 16.200(*) | 1.764 | .000 | 9.691 | 22.709 |
| 2 | 12.000(*) | 1.280 | .000 | 7.277 | 16.723 | |
| 3 | 5.800 | 1.690 | .075 | -.436 | 12.036 | |
| 5 | -11.650(*) | 1.551 | .000 | -17.373 | -5.927 | |
| 5 | 1 | 27.850(*) | 2.398 | .000 | 19.002 | 36.698 |
| 2 | 23.650(*) | 2.045 | .000 | 16.103 | 31.197 | |
| 3 | 17.450(*) | 2.006 | .000 | 10.048 | 24.852 | |
| 4 | 11.650(*) | 1.551 | .000 | 5.927 | 17.373 | |
| * The mean difference is significant at the .05 level. | ||||||
| a Adjustment for multiple comparisons: Bonferroni. | ||||||
This shows that there was only one pair for which there was no significant difference: 40% weedkiller followed by 2 minutes flame thrower, and 2 minutes flame thrower followed by 40% weedkiller. The differences for all the other pairs are significant. It does not matter if the farmer uses weedkiller or a flamethrower, but how much weedkiller and how long a burst of flame does make a difference to weed control.
Formal report:
| There was a significant main effect of the type of treatment, F(1,
9) = 34.08, p < .001. There was a significant main effect of the severity of treatment, F(2.21, 19.88) = 83.49, p <.001. |
© MicrobiologyBytes 2007.